Blood Cancer News and Research

RSS

Cancer-killing T cells release chemicals to direct swarms towards tumors

When immune system T cells find and recognise a target, they release chemicals to attract more T cells which then swarm to help subdue the threat, shows a new study published today in eLife.

13 Oct 2020

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

8 Oct 2020

UM171 molecule saves life of young man suffering from severe aplastic anemia

In a world first, a young man suffering from severe aplastic anemia who could not be helped by standard treatments has been given a life-saving blood transplant with the made-in-Canada UM171 molecule.

30 Sep 2020

New partnership aims to advance predictive tests for multiple myeloma in Ireland

By combining genomic testing and next generation sequencing technology, a new partnership led by RCSI researchers aims to advance predictive tests for multiple myeloma, the second most common blood cancer in Ireland.

18 Sep 2020

Convalescent plasma could be an effective treatment for children with COVID-19

Early findings from researchers at Children's Hospital of Philadelphia (CHOP) show that convalescent plasma appears to be a safe and possibly effective treatment for children with life-threatening cases of COVID-19.

9 Sep 2020

PI3K/mTOR and topoisomerase inhibitors suggested as candidates to reduce expression of ACE2

A recent study published in the preprint server medRxiv in September 2020 shows that the already approved drug families called P13K/mTOR and topoisomerase inhibitors may be useful in reducing individual susceptibility to the virus.

7 Sep 2020

New consortium established to study the characteristics of blood cells

What's the risk of different human populations to develop a disease? To find out, a team led by Université de Montréal professor Guillaume Lettre created an international consortium to study the blood of hundreds of thousands of people worldwide.

4 Sep 2020

Major UK study launched to assess the impact of COVID-19 on cancer patients

A new UK study has been launched to assess the impact of covid-19 on people with cancer.

2 Sep 2020

Blood cancer patients are more vulnerable to the effects of COVID-19, study finds

A newly published study led by the Universities of Oxford and Birmingham has found that, compared to other cancers, patients with blood cancers are more vulnerable to the effects of the coronavirus pandemic.

25 Aug 2020

A metabolic enzyme shows great potential as target for immunotherapies

The metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promotes the spread of tumor cells and suppresses the immune system.

20 Aug 2020

Scientists identify genetic link to predict treatment response in patients with aggressive blood cancer

A Singapore team led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) discovered a genetic link to better predict treatment response for relapsed/refractory patients with natural- killer T-cell lymphoma (NKTCL), a highly aggressive form of blood cancer.

13 Aug 2020

New alpha-radioimmunotherapy for multiple myeloma shows promise in preclinical study

A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of the Journal of Nuclear Medicine. Given the long half-life, central production and worldwide distribution of 212Pb-anti-CD38, researchers have determined that the α-radioimmunotherapy is not only effective but also clinically feasible as a multiple myeloma treatment.

6 Aug 2020

Study reveals impact of TP53 gene mutations on MDS severity

Considered the "guardian of the genome," TP53 is the most commonly mutated gene in cancer. TP53's normal function is to detect DNA damage and prevent cells from passing this damage on to daughter cells.

3 Aug 2020

Study sheds light on potential new treatment approach in AML patients

Tyrosine kinases are protein enzymes that have many functions within cells, including cell signaling, growth, and division. Sometimes these enzymes can be overactive, which helps cancer cells survive and multiply.

31 Jul 2020

Waterloo tech profiles antibodies in blood of COVID-19 patients

A world-leading University of Waterloo spinoff company, that decodes blood samples for potential treatments for illnesses like cancer and COVID-19, is expanding operations with the help of a $5-million USD investment.

29 Jul 2020

Josep Carreras Institute's spin-off aims to develop new immuno-oncological therapeutic tools

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's (Government of Catalonia) CERCA network, has created the OneChain Immunotherapeutics spin-off, the aim of which is to develop new immuno-oncological therapeutic tools with various preclinical candidates, based on CAR-T technology for different tumors, such as cortical T-cell acute lymphoblastic leukemia (coT-ALL), a rare subtype of leukemia that mainly affects children, and which has a poor prognosis.

20 Jul 2020

Anaplastic large cell lymphoma: Defense mechanism against certain drugs promotes cancer growth

A general problem encountered in cancer therapy is that many patients develop resistance to a drug over the course of treatment.

15 Jul 2020

New NCCN guidelines explain how to recognize and manage immunotherapy-related side effects

The National Comprehensive Cancer Network today announced the completion of the new NCCN Guidelines for Patients®: Immunotherapy Side Effects series, with the publication of a book focused on chimeric antigen receptor (CAR) T-cell therapy. This closely follows the publication of a separate book on immune checkpoint inhibitors, both created with support from the NCCN Foundation®.

1 Jul 2020

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field.